GTBP
NASDAQ
$0.34
GT Biopharma Inc (GTBP)
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.
Sector:
Healthcare
Industry:
Biotechnology
Target: $3 (+779.77%)
Market Cap
$12M
FCF 5Y CAGR
+20.62%
Free Cash Flow Yield
-92.16%
Beta (5Y)
1.57
Price Chart
Valuation
Market Cap$12M
Forward P/E17.33
PEG1.05
P/S204.96
P/B1.83
Profitability
EBITDA-$8.09M
EPS-$1.34
Financial Health
Free Cash Flow Yield-92.16%
Growth & Risk
FCF 5Y CAGR+20.62%
Beta (5Y)1.57
Sharpe Ratio-0.83